215 related articles for article (PubMed ID: 26508513)
61. Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.
Prathipati PK; Mandal S; Pon G; Vivekanandan R; Destache CJ
Pharm Res; 2017 Dec; 34(12):2749-2755. PubMed ID: 28905173
[TBL] [Abstract][Full Text] [Related]
62. Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis.
Laeyendecker O; Redd AD; Nason M; Longosz AF; Karim QA; Naranbhai V; Garrett N; Eshleman SH; Abdool Karim SS; Quinn TC
J Infect Dis; 2015 Sep; 212(5):754-9. PubMed ID: 25712973
[TBL] [Abstract][Full Text] [Related]
63. Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
Dickinson L; Yapa HM; Jackson A; Moyle G; Else L; Amara A; Khoo S; Back D; Karolia Z; Higgs C; Boffito M
Antimicrob Agents Chemother; 2015 Oct; 59(10):6080-6. PubMed ID: 26195515
[TBL] [Abstract][Full Text] [Related]
64. Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy.
Lê MP; Landman R; Koulla-Shiro S; Charpentier C; Sow PS; Diallo MB; Ngom Gueye NF; Ngolle M; Le Moing V; Eymard-Duvernay S; Benalycherif A; Delaporte E; Girard PM; Peytavin G;
J Antimicrob Chemother; 2015 May; 70(5):1517-21. PubMed ID: 25583749
[TBL] [Abstract][Full Text] [Related]
65. Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy.
Kerr SJ; Punyawudho B; Thammajaruk N; Colbers A; Chaiyahong P; Phonphithak S; Sapsirisavat V; Ruxrungtham K; Burger DM; Avihingsanon A
AIDS Res Hum Retroviruses; 2015 Apr; 31(4):368-74. PubMed ID: 25384393
[TBL] [Abstract][Full Text] [Related]
66. Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study.
Lacey CJ; Wright A; Weber JN; Profy AT
AIDS; 2006 Apr; 20(7):1027-30. PubMed ID: 16603855
[TBL] [Abstract][Full Text] [Related]
67. Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients
.
Yamada E; Takagi R; Tanabe Y; Fujiwara H; Hasegawa N; Kato S
Int J Clin Pharmacol Ther; 2017 Jul; 55(7):567-570. PubMed ID: 28427498
[TBL] [Abstract][Full Text] [Related]
68. Extent of In Utero Transfer of Tenofovir From Mother to Fetus: A Paired Analysis of Hair Specimens Collected at Birth From a Cohort in the United States.
Pintye J; Huo Y; Kacanek D; Zhang K; Kuncze K; Okochi H; Gandhi M
J Infect Dis; 2021 Feb; 223(4):638-644. PubMed ID: 32620015
[TBL] [Abstract][Full Text] [Related]
69. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
Weis JF; Baeten JM; McCoy CO; Warth C; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Mugo N; Matsen FA; Celum C; Lehman DA;
AIDS; 2016 Jan; 30(1):31-5. PubMed ID: 26731753
[TBL] [Abstract][Full Text] [Related]
70. Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs.
Cunha-Reis C; Machado A; Barreiros L; Araújo F; Nunes R; Seabra V; Ferreira D; Segundo MA; Sarmento B; das Neves J
J Control Release; 2016 Dec; 243():43-53. PubMed ID: 27664327
[TBL] [Abstract][Full Text] [Related]
71. Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya.
Mugo NR; Mudhune V; Heffron R; Thomas KK; McLellan-Lemal E; Njoroge B; Peacock S; O'Connor SM; Nyagol B; Ouma E; Ridzon R; Wiener J; Isoherranen N; Erikson DW; Ouattara LA; Yousefieh N; Jacot TA; Haaland RE; Morrison SA; Haugen HS; Thurman AR; Allen SA; Baeten JM; Samandari T; Doncel GF
Front Reprod Health; 2023; 5():1118030. PubMed ID: 37383290
[TBL] [Abstract][Full Text] [Related]
72. Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.
Ngandu NK; Carlson JM; Chopera DR; Ndabambi N; Abdool Karim Q; Abdool Karim S; Williamson C
J Acquir Immune Defic Syndr; 2017 Sep; 76(1):43-47. PubMed ID: 28797020
[TBL] [Abstract][Full Text] [Related]
73. Computational Modeling of Antiviral Drug Diffusion from Poly(lactic- co-glycolic-acid) Fibers and Multicompartment Pharmacokinetics for Application to the Female Reproductive Tract.
Halwes ME; Tyo KM; Steinbach-Rankins JM; Frieboes HB
Mol Pharm; 2018 Apr; 15(4):1534-1547. PubMed ID: 29481088
[TBL] [Abstract][Full Text] [Related]
74. Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa.
MacQueen KM; Dlamini S; Perry B; Okumu E; Sortijas S; Singh C; Pillay D; Majors A; Jerome S; Watson S; Karim SA; Karim QA; Mansoor LE
AIDS Behav; 2016 Nov; 20(11):2682-2691. PubMed ID: 26945585
[TBL] [Abstract][Full Text] [Related]
75. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
[TBL] [Abstract][Full Text] [Related]
76. Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study.
van der Straten A; Brown ER; Marrazzo JM; Chirenje MZ; Liu K; Gomez K; Marzinke MA; Piper JM; Hendrix CW;
J Int AIDS Soc; 2016; 19(1):20642. PubMed ID: 26850270
[TBL] [Abstract][Full Text] [Related]
77. Octadecyloxyethyl benzyl tenofovir: A novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate.
Beadle JR; Aldern KA; Zhang XQ; Valiaeva N; Hostetler KY; Schooley RT
Antiviral Res; 2019 Nov; 171():104614. PubMed ID: 31550449
[TBL] [Abstract][Full Text] [Related]
78. Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment.
Calcagno A; Cusato J; Marinaro L; Simiele M; Lucchiari M; Alcantarini C; Tettoni MC; Trentini L; Mengozzi G; D'Avolio A; Di Perri G; Bonora S
AIDS; 2016 Mar; 30(6):915-20. PubMed ID: 26636928
[TBL] [Abstract][Full Text] [Related]
79. Sensitivity Analysis of a Pharmacokinetic Model of Vaginal Anti-HIV Microbicide Drug Delivery.
Jarrett AM; Gao Y; Hussaini MY; Cogan NG; Katz DF
J Pharm Sci; 2016 May; 105(5):1772-1778. PubMed ID: 27012224
[TBL] [Abstract][Full Text] [Related]
80. MALDI Mass Spectrometry Imaging Reveals Heterogeneous Distribution of Tenofovir and Tenofovir Diphosphate in Colorectal Tissue of Subjects Receiving a Tenofovir-Containing Enema.
Seneviratne HK; Hendrix CW; Fuchs EJ; Bumpus NN
J Pharmacol Exp Ther; 2018 Oct; 367(1):40-48. PubMed ID: 30037813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
